A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

Inclusion Criteria: * Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. participation in genetics research, completion of the electronic diary cards, return for follow-up visits). * Written informed consent obtained from the participant prior to performance of any study specific procedure. * Healthy participants as established by medical history and clinical examination before entering into the study. * A male or female participant between, and including, 18 and 40 years of age at the time of the first vaccination. * Body Mass Index \>18 Kg/m\^2 and \<35 Kg/m\^2. * Participants with following hematological/biochemical parameters: * White Blood Cells and differential, within the study designated laboratory normal range. Participants with FDA toxicity grade 1 differential cell counts and considered not clinically significant may be enrolled at the discretion of the investigator, and with the review and approval of the medical monitor. * Platelets = 125,000 - 500,000 cells/mm\^3 * Hemoglobin within normal range of the study designated laboratory * Alanine aminotransferase within the study designated laboratory normal range * Aspartate aminotransferase within the study designated laboratory normal range * Total bilirubin within the study designated laboratory normal range * Alkaline phosphatase within the study designated laboratory normal range * Serum creatinine less than or equal to 1.1 times…